Mirum Pharmaceuticals Inc. - notizie pubblicate 221 - letture 3.027
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
- chmp opinion based on pivotal iconic study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile a ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
- six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with alagille syndrome (algs) - characterization of four-yea ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on october 10, 2022, the compensation committee of mirum's board of directors ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on september 10-11, 2022, the compensation committee of mirum's board of dire ...
MIRUM PHARMACEUTICALS INC.
Automatic Shelf Registration Statement - Form S-3ASR
S-3asr table of contents as filed with the securities and exchange commission on september 9, 2022 registration no. 333- united states securities and exchange commission washington ...
MIRUM PHARMACEUTICALS INC.
Management Change/Compensation - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm), a biopharmaceutical company focused on the identification, acquisition, development and commercia ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Completion of Acquisition or Disposition of Assets - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership (Form 4)
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti